The recommended starting dosage of Toviaz in adults is 4 mg orally once daily. Based upon individual response and tolerability, increase to the maximum dosage of Toviaz 8 mg once daily. For administration instructions, see Dosage and Administration (2.6).
Pediatric Patients Weighing Greater than 25 kg and up to 35 kg
The recommended dosage of Toviaz is 4 mg orally once daily. If needed, dosage may be increased to Toviaz 8 mg orally once daily. For administration instructions, see Dosage and Administration (2.6).
Pediatric Patients Weighing Greater than 35 kg
The recommended starting dosage of Toviaz is 4 mg orally once daily. After one week, increase to Toviaz 8 mg orally once daily. For administration instructions, see Dosage and Administration (2.6).
The recommended dosage of Toviaz in adult patients with renal impairment is described in Table 1 [see Use in Specific Populations (8.6)]. For administration instructions, see Dosage and Administration (2.6).
| Estimated Creatinine Clearance* | Recommended Dose |
|---|---|
| |
CLcr 30 to 89 mL/min | 8 mg |
CLcr 15 to 29 mL/min | 4 mg |
CLcr <15 mL/min | 4 mg |
Pediatric Patients Weighing Greater than 25 kg and up to 35 kg
The recommended dosage of Toviaz in pediatric patients with renal impairment weighing greater than 25 kg and up to 35 kg is described in Table 2 [see Use in Specific Populations (8.6)]. For administration instructions, see Dosage and Administration (2.6).
| Estimated Glomerular Filtration Rate (GFR)* | Recommended Dose† |
|---|---|
eGFR 30 to 89 mL/min/1.73m† | 4 mg |
eGFR 15 to 29 mL/min/1.73m† | Use is Not Recommended |
eGFR <15 mL/min/1.73m2 or requiring dialysis | Use is Not Recommended |
Pediatric Patients weighing greater than 35 kg
The recommended dosage of Toviaz in pediatric patients with renal impairment weighing greater than 35 kg is described in Table 3 [see Use in Specific Populations (8.6)]. For administration instructions, see Dosage and Administration (2.6).
Table 3: Toviaz Recommended Dose in Pediatric Patients Aged 6 Years and Older Weighing Greater Than 35 kg With Renal Impairment (Administered Orally Once Daily)
| |
Estimated GFR* | Recommended Dose† |
eGFR 30 to 89 mL/min/1.73m‡ | 8 mg‡ |
eGFR15 to 29 mL/min/1.73m‡ | 4 mg |
eGFR <15 mL/min/1.73m2 or requiring dialysis | Use is Not Recommended |
Adult Patients with OAB
The maximum recommended dosage is Toviaz 4 mg orally once daily in adult patients taking strong CYP3A4 inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. For administration instructions, see Dosage and Administration (2.6).
Pediatric Patients with NDO
Pediatric Patients Weighing Greater than 25 kg and up to 35 kg
The use of Toviaz in pediatric patients weighing greater than 25 kg and up to 35 kg and taking strong CYP3A4 inhibitors is not recommended [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. For administration instructions, see Dosage and Administration (2.6).
Pediatric Patients Weighing Greater than 35 kg
The maximum recommended dosage is Toviaz 4 mg orally once daily in pediatric patients weighing greater than 35 kg and taking strong CYP3A4 inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. For administration instructions, see Dosage and Administration (2.6).
Swallow Toviaz whole with liquid. Do not chew, divide, or crush. Take with or without food [see Clinical Pharmacology (12.3)].
The recommended starting dosage of Toviaz in adults is 4 mg orally once daily. Based upon individual response and tolerability, increase to the maximum dosage of Toviaz 8 mg once daily. For administration instructions, see Dosage and Administration (2.6).
Pediatric Patients Weighing Greater than 25 kg and up to 35 kg
The recommended dosage of Toviaz is 4 mg orally once daily. If needed, dosage may be increased to Toviaz 8 mg orally once daily. For administration instructions, see Dosage and Administration (2.6).
Pediatric Patients Weighing Greater than 35 kg
The recommended starting dosage of Toviaz is 4 mg orally once daily. After one week, increase to Toviaz 8 mg orally once daily. For administration instructions, see Dosage and Administration (2.6).
The recommended dosage of Toviaz in adult patients with renal impairment is described in Table 1 [see Use in Specific Populations (8.6)]. For administration instructions, see Dosage and Administration (2.6).
| Estimated Creatinine Clearance* | Recommended Dose |
|---|---|
| |
CLcr 30 to 89 mL/min | 8 mg |
CLcr 15 to 29 mL/min | 4 mg |
CLcr <15 mL/min | 4 mg |
Pediatric Patients Weighing Greater than 25 kg and up to 35 kg
The recommended dosage of Toviaz in pediatric patients with renal impairment weighing greater than 25 kg and up to 35 kg is described in Table 2 [see Use in Specific Populations (8.6)]. For administration instructions, see Dosage and Administration (2.6).
| Estimated Glomerular Filtration Rate (GFR)* | Recommended Dose† |
|---|---|
eGFR 30 to 89 mL/min/1.73m† | 4 mg |
eGFR 15 to 29 mL/min/1.73m† | Use is Not Recommended |
eGFR <15 mL/min/1.73m2 or requiring dialysis | Use is Not Recommended |
Pediatric Patients weighing greater than 35 kg
The recommended dosage of Toviaz in pediatric patients with renal impairment weighing greater than 35 kg is described in Table 3 [see Use in Specific Populations (8.6)]. For administration instructions, see Dosage and Administration (2.6).
Table 3: Toviaz Recommended Dose in Pediatric Patients Aged 6 Years and Older Weighing Greater Than 35 kg With Renal Impairment (Administered Orally Once Daily)
| |
Estimated GFR* | Recommended Dose† |
eGFR 30 to 89 mL/min/1.73m‡ | 8 mg‡ |
eGFR15 to 29 mL/min/1.73m‡ | 4 mg |
eGFR <15 mL/min/1.73m2 or requiring dialysis | Use is Not Recommended |
Adult Patients with OAB
The maximum recommended dosage is Toviaz 4 mg orally once daily in adult patients taking strong CYP3A4 inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. For administration instructions, see Dosage and Administration (2.6).
Pediatric Patients with NDO
Pediatric Patients Weighing Greater than 25 kg and up to 35 kg
The use of Toviaz in pediatric patients weighing greater than 25 kg and up to 35 kg and taking strong CYP3A4 inhibitors is not recommended [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. For administration instructions, see Dosage and Administration (2.6).
Pediatric Patients Weighing Greater than 35 kg
The maximum recommended dosage is Toviaz 4 mg orally once daily in pediatric patients weighing greater than 35 kg and taking strong CYP3A4 inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]. For administration instructions, see Dosage and Administration (2.6).
Swallow Toviaz whole with liquid. Do not chew, divide, or crush. Take with or without food [see Clinical Pharmacology (12.3)].
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.